Physician profile
Ann Mathew
NPI 1265951487
$1,777.36
in general payments reported to CMS, 2019-2025
17 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $413 · 2022: $109 · 2023: $404 · 2024: $443 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,255.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,255.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $394.94 | 2023-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $350.54 | 2023-2025 | Fintepla |
| Sk Life Science, INC. | $247.84 | 2024-2025 | Xcopri |
| Neurelis, INC. | $123.42 | 2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $105.30 | 2021 | |
| Genzyme Corporation | $100.69 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $91.52 | 2023-2024 | Aptiom |
| Biohaven Pharmaceuticals, INC. | $81.38 | 2021 | |
| Abbvie INC. | $70.73 | 2021-2025 | |
| Emd Serono, INC. | $47.56 | 2021 | |
| Lilly USA, LLC | $46.32 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $22.93 | 2022 | |
| Biogen, INC. | $21.81 | 2021 | |
| Acadia Pharmaceuticals INC | $20.75 | 2024 | Daybue |
| Novartis Pharmaceuticals Corporation | $20.13 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.